Who are Sulfamylon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ethamide, 2-Chromenone, Zonegran, Topamax, Silymarin, Azopt.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mafenide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sulfamylon — Competitive Intelligence Brief

Sulfamylon (MAFENIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Methylated Sulfonamide Antibacterial. Area: Metabolic.

marketed Methylated Sulfonamide Antibacterial Carbonic anhydrase 12 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Sulfamylon (MAFENIDE) — Rising.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sulfamylon TARGET	MAFENIDE	Rising	marketed	Methylated Sulfonamide Antibacterial	Carbonic anhydrase 12	1969-01-01
Ethamide	ETHOXZOLAMIDE	Pfizer	marketed	ethoxzolamide	Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13	1982-01-01
2-Chromenone	COUMARIN		marketed	coumarin	Induced myeloid leukemia cell differentiation protein Mcl-1, Carbonic anhydrase 1, Carbonic anhydrase 12
Zonegran	Zonegran	Dr. Reddy's Laboratories Limited	marketed		Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12
Topamax	topiramate	Janssen	marketed		Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12
Silymarin	Silymarin	F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica	marketed	silymarin	Urokinase-type plasminogen activator, Carbonic anhydrase 1, Carbonic anhydrase 12
Azopt	Azopt	Alcon Research	marketed		Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13

Recent regulatory actions (last 90 days)

2026-03-18 — Topamax · FDA · approved · US · Janssen

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-16 — Topamax · 9622983 · Formulation · US
2027-11-16 — Topamax · 8663683 · Formulation · US
2027-11-16 — Topamax · 8992989 · Formulation · US
2027-11-16 — Topamax · 8889191 · Method of Use · US
2027-11-16 — Topamax · 9549940 · Formulation · US
2027-11-16 — Topamax · 8298580 · Formulation · US
2027-11-16 — Topamax · 8877248 · Formulation · US
2027-11-16 — Topamax · 9555004 · Formulation · US
2027-11-16 — Topamax · 10314790 · Formulation · US
2028-04-04 — Topamax · 8298576 · Formulation · US
2033-03-19 — Topamax · 10363224 · Method of Use · US
2033-03-19 — Topamax · 9555005 · Formulation · US
2033-03-19 — Topamax · 9101545 · Formulation · US
2033-03-19 — Topamax · 8889190 · Formulation · US
2033-03-19 — Topamax · 8652527 · Formulation · US
2040-08-21 — Topamax · 11826343 · Formulation · US
2040-08-21 — Topamax · 11433046 · Method of Use · US
2040-08-21 — Topamax · 11633374 · Formulation · US
2040-08-21 — Topamax · 12290503 · Formulation · US
2040-08-21 — Topamax · 11911362 · Formulation · US

Sponsor landscape (Methylated Sulfonamide Antibacterial class)

Rising · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sulfamylon — Competitive Intelligence Brief. https://druglandscape.com/ci/mafenide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab